Vimal Elaichi Delhi HC: Petitions Against Maharashtra FDA Notice

• PB Agro, makers of Vimal Elaichi, petitioned the Delhi High Court to quash Maharashtra FDA show-cause notices issued to actors Shah Rukh Khan, Ajay Devgn, and Tiger Shroff.
• The Maharashtra FDA alleged Vimal Elaichi ads are surrogate promotions for banned Vimal Pan Masala and demanded documentation from actors, campaign halt, and material withdrawal.
• PB Agro argued the FDA lacked jurisdiction to halt ads, the notice was sent only to actors causing the company irreparable harm, and surrogate advertising claims were baseless as "Vimal pan masala has not been manufactur."
• Justice Swarana Kanta Sharma of the Delhi High Court has reserved her verdict on the crucial question of the court's jurisdiction to hear the matter.

This case serves as a critical reminder for compliance officers to meticulously review advertising campaigns for any potential interpretation as surrogate advertising for banned items, especially given the involvement of high-profile figures like Shah Rukh Khan, Ajay Devgn, and Tiger Shroff.

PB Agro, the manufacturer of Vimal Elaichi, has initiated legal proceedings in the Delhi High Court. The company seeks to nullify show-cause notices that were issued by the Maharashtra Food and Drugs Administration (FDA) to prominent Bollywood actors Shah Rukh Khan, Ajay Devgn, and Tiger Shroff, who serve as brand ambassadors for Vimal Elaichi. This legal action highlights a significant dispute over advertising practices and regulatory oversight.

The core of the Maharashtra FDA's concern revolves around allegations that advertisements for "Vimal Elaichi" are, in essence, a form of surrogate promotion for "Vimal Pan Masala." The latter is a chewable product that is currently banned from sale and consumption within the state of Maharashtra. The regulatory body's notices specifically instructed the celebrity endorsers to furnish documentation proving that Vimal Elaichi is a distinct product, separate from the prohibited pan masala.

Furthermore, the Maharashtra FDA's directives extended beyond mere information requests. The agency demanded an immediate cessation of the promotional campaign associated with Vimal Elaichi and the removal of all related advertising materials from various digital platforms. This comprehensive demand underscores the state regulator's intent to curb what it perceives as indirect advertising for a banned substance, placing the onus of compliance directly on the celebrity figures involved.

Represented by Senior Advocates Dayan Krishnan and Mohit Mathur, PB Agro presented several key arguments to the Delhi High Court. A central contention was that the FDA's notice, dated August 11, 2026, was exclusively dispatched to the actors and not to the company itself. PB Agro asserts that despite this, it is the company that stands to suffer "irreparable harm" as a direct consequence of the regulatory action, making its petition to the court a necessary step for redress.

The company also mounted a direct challenge to the Maharashtra FDA's authority, arguing that the state regulator lacked the necessary jurisdiction to issue directives aimed at halting its advertising campaigns. This jurisdiction challenge advertising regulation forms a critical component of PB Agro's Delhi High Court petition, questioning the geographical and legal scope of the Food and Drugs Administration India's powers when it comes to national advertising.

Moreover, PB Agro vehemently denied the allegations of surrogate advertising. The company stated in its petition that such claims were "baseless," asserting that "Vimal pan masala has not been manufactur." This argument aims to dismantle the very foundation of the FDA's case by suggesting that the product allegedly being surrogately advertised either does not exist or is not produced in a manner that would justify the FDA's claims.

The Delhi High Court, specifically Justice Swarana Kanta Sharma, is currently deliberating on a pivotal aspect of this case: the question of jurisdiction. Justice Sharma has reserved her verdict on whether the Delhi High Court possesses the legal authority to entertain and decide upon the matter brought forth by PB Agro. This initial ruling will determine the appropriate forum for the dispute, rather than immediately addressing the merits of the surrogate advertising claims.

This procedural step is a common but significant hurdle in inter-state legal disputes, particularly when national advertising campaigns are involved and regulatory bodies from different states might assert authority. The court's decision on this jurisdictional point is crucial, as it will establish whether a company can challenge a state-level regulatory notice concerning advertising practices in a different state's high court.

This ongoing legal battle, centered around the Vimal Elaichi Delhi HC Maharashtra FDA notice, carries substantial implications for the landscape of advertising regulation in India. It underscores the increasing scrutiny faced by brands and their celebrity endorsers, particularly when products like Vimal Elaichi are perceived to be linked to items such as Vimal Pan Masala, which are subject to bans or strict regulations by the Food and Drugs Administration India.

The outcome of PB Agro's Delhi High Court petition, especially regarding the jurisdiction challenge advertising regulation, could set a significant precedent. It will clarify the avenues available for companies to contest show-cause notices issued by state regulatory bodies like the Maharashtra FDA, particularly when those notices target actors involved in national campaigns. This case serves as a critical reminder for compliance officers to meticulously review advertising campaigns for any potential interpretation as surrogate advertising for banned items, especially given the involvement of high-profile figures like Shah Rukh Khan, Ajay Devgn, and Tiger Shroff.

Compliance officers should review advertising campaigns for products that could be construed as surrogate advertising for banned items, particularly when celebrity endorsements are involved. Legal teams should monitor the Delhi High Court's decision on jurisdiction, as it could set a precedent for challenging state regulatory notices on advertising practices, impacting where and how such challenges can be mounted by companies operating nationally.

Source: Original reporting via legal news outlets